Skip to main content

Panbela Therapeutics, Inc. (PBLA)

NASDAQ: PBLA · IEX Real-Time Price · USD
2.03 -0.08 (-3.79%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap27.53M
Revenue (ttm)n/a
Net Income (ttm)-6.99M
Shares Out10.09M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,447
Open2.12
Previous Close2.11
Day's Range1.96 - 2.09
52-Week Range1.91 - 8.80
Beta0.19
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 10, 2021

About PBLA

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Thera...

IndustryBiotechnology
Founded2011
CEOMichael Cullen
Employees5
Stock ExchangeNASDAQ
Ticker SymbolPBLA
Full Company Profile

Financial Performance

Financial Statements

News

Panbela to Present at Upcoming Investor Conferences

MINNEAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

1 month ago - GlobeNewsWire

Panbela Provides Business Update and Reports Q2 2021 Financial Results

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...

2 months ago - GlobeNewsWire

Panbela to Present at Access to Giving Virtual Conference on July 15, 2021, at 10:30 a.m. ET

MINNEAPOLIS, July 07, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

3 months ago - GlobeNewsWire

PANBELA THERAPEUTICS ANNOUNCES CLOSING OF $10.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for t...

3 months ago - GlobeNewsWire

Panbela Therapeutics Shares Drop On Raising $10M Via Equity Issued At 21% Discount

Panbela Therapeutics Inc (NASDAQ: PBLA) has increased the size of the previously announced public offering to around 3.3 million common shares from 1.7 million shares at $3.00 per share. The offering wi...

3 months ago - Benzinga

PANBELA THERAPEUTICS INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING OF COMMON STOCK TO $10.0 MILLION

MINNEAPOLIS, June 30, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for t...

3 months ago - GlobeNewsWire

PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for t...

3 months ago - GlobeNewsWire

Panbela Set to Join Russell Microcap® Index

MINNEAPOLIS, June 08, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...

4 months ago - GlobeNewsWire

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitax...

MINNEAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...

4 months ago - GlobeNewsWire

Panbela Provides Business Update and Reports Q1 2021 Financial Results

MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with ...

5 months ago - GlobeNewsWire

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

6 months ago - GlobeNewsWire

Corrected: Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results

MINNEAPOLIS, March 26, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), is re-issuing this press release solely to correct an inadvertent decimal error in the net loss per share repor...

6 months ago - GlobeNewsWire

Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results

MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

6 months ago - GlobeNewsWire

Panbela Schedules Conference Call on March 25, 2021 to Report 2020 Fourth Quarter Financial Results

MINNEAPOLIS, March 17, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit...

7 months ago - GlobeNewsWire

Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs

MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi...

7 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Panbela Therapeutics Inc. - PBLA

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Panbela Therapeutics Inc. ("Panbela" or the "Company") (NASDAQ: PBLA). Such investors are advised ...

8 months ago - PRNewsWire

DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank

Independent data safety monitoring board (DSMB) has recommended a hold on Panbela Therapeutics Inc's (NASDAQ: PBLA) ongoing Phase 1 trial to hold the administration of SBP-101 pending further investigat...

8 months ago - Benzinga

Panbela Announces Research Agreement with Johns Hopkins University School of Medicine

MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with...

8 months ago - GlobeNewsWire

Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.

MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer...

10 months ago - GlobeNewsWire